CV Therapeutics Inks Ex-U.S. Ranexa Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
With Menarini, angina drug will launch in the U.K. and Germany early next year.
You may also be interested in...
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.
FDA To Send Draft Ranexa Label Shortly
CV Therapeutics CEO is bullish on clearance in first-line angina.